CapitalRankings
  • Money
  • Banking
  • Investment
  • Trading
  • World News
  • Business
☰
✖
  • Money
  • Banking
  • Investment
  • Trading
  • World News
  • Business

FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults

Pfizer and the FDA view Paxlovid as an important complementary tool to vaccination that can help high-risk Americans manage their Covid infections.
READ FULL ARTICLE

Related posts

EV maker Lucid announces $3 billion raise from Saudi public wealth fund and stock offering


Read more

This startup wants to curb fast fashion by helping you rent out your closet


Read more

    CATEGORIES

    • Banking
    • Business
    • Investment
    • Money
    • Trading
    • World News

    ARCHIVES

    LATEST POSTS

    • TripAdvisor rival GetYourGuide nears $2 billion valuation as it raises fresh funds to invest in A.I.
    • Singapore PM Lee tests positive for Covid again in rebound case, says he feels fine
    • Singapore overtakes Hong Kong as the most expensive Asia-Pacific city for private homes
    • Southeast Asia’s digital economy may be set to hit $1 trillion, but roadblocks remain
    • Stocks making the biggest moves after hours: C3.ai, Nordstrom, Salesforce, CrowdStrike and more

Signup for Alerts and Newsletters!

Exclusive Market-Impacting News & Reports.

Know what’s hot, what’s innovative, and where the deals are with deep news and reports coverage. Join us now!



    Recent posts

    • TripAdvisor rival GetYourGuide nears $2 billion valuation as it raises fresh funds to invest in A.I.
    • Singapore PM Lee tests positive for Covid again in rebound case, says he feels fine
    • Singapore overtakes Hong Kong as the most expensive Asia-Pacific city for private homes
    CapitalRankings
    720 999 W. Broadway
    Vancouver, BC
    V5Z1K3 Canada
    ©2022 Capital Rankings. All Rights Reserved. Privacy Policy

    Get Exclusive Market-Impacting News & Reports.

    Know what’s hot, what’s innovative, and where the deals are with in-depth news and reporting coverage.
    Join us now!





      Erhalten Sie exklusive, marktbeeinflussende Nachrichten und Berichte.

      Erfahren Sie, was angesagt ist, was innovativ ist und wo die Geschäfte laufen – mit ausführlichen Nachrichten und Berichten. Melden Sie sich jetzt an!